The online version of this article (https://doi.org/10.1186/s12974-018-1060-5) contains supplementary material, which is available to authorized users.
Neuroprotection with cannabinoids in Parkinson’s disease (PD) has been afforded predominantly with antioxidant or anti-inflammatory cannabinoids. In the present study, we investigated the anti-inflammatory and neuroprotective properties of VCE-003.2, a quinone derivative of the non-psychotrophic phytocannabinoid cannabigerol (CBG), which may derive its activity at the peroxisome proliferator-activated receptor-γ (PPARγ). The compound is also an antioxidant.
We evaluated VCE-003.2 in an in vivo [mice subjected to unilateral intrastriatal injections of lipopolysaccharide (LPS)] model of PD, as well as in in vitro (LPS-exposed BV2 cells and M-213 cells treated with conditioned media generated from LPS-exposed BV2 cells) cellular models. The type of interaction of VCE-003.2 at the PPARγ receptor was furtherly investigated in bone marrow-derived human mesenchymal stem cells (MSCs) and sustained with transcriptional assays and in silico docking studies.
VCE-003.2 has no activity at the cannabinoid receptors, a fact that we confirmed in this study using competition studies. The administration of VCE-003.2 to LPS-lesioned mice attenuated the loss of tyrosine hydroxylase (TH)-containing nigrostriatal neurons and, in particular, the intense microgliosis provoked by LPS in the substantia nigra, measured by Iba-1/Cd68 immunostaining. The analysis by qPCR of proinflammatory mediators such as tumor necrosis factor-α (TNF-α), interleukin-1β (IL-1β), and inducible nitric oxide synthase (iNOS) in the striatum showed they were markedly elevated by the LPS lesion and strongly reduced by the treatment with VCE-003.2. The effects of VCE-003.2 in LPS-lesioned mice implied the activation of PPARγ receptors, as they were attenuated when VCE-003.2 was co-administered with the PPARγ inhibitor T0070907. We then moved to some in vitro approaches, first to confirm the anti-inflammatory profile of VCE-003.2 in cultured BV2 cells exposed to LPS. VCE-003.2 was able to attenuate the synthesis and release of TNF-α and IL-1β, as well as the induction of iNOS and cyclooxygenase-2 (COX-2) elicited by LPS in these cells. However, we found such effects were not reversed by GW9662, another classic PPARγ antagonist. Next, we investigated the neuroprotective effects of VCE-003.2 in cultured M-213 neuronal cells exposed to conditioned media generated from LPS-exposed cultured BV2 cells. VCE-003.2 reduced M-213 cell death, but again, such effects were not reversed by T0070907. Using docking analysis, we detected that VCE-003.2 binds both the canonical and the alternative binding sites in the PPARγ ligand-binding pocket (LBP). Functional assays further showed that T0070907 almost abolished PPARγ transcriptional activity induced by rosiglitazone (RGZ), but it did not affect the activity of VCE-003.2 in a Gal4-Luc system. However, T0070907 inhibited the effects of RGZ and VCE-003.2 on the expression of PPARγ-dependent genes upregulated in MSCs.
We have demonstrated that VCE-003.2 is neuroprotective against inflammation-driven neuronal damage in an in vivo model of PD and in in vitro cellular models of neuroinflammation. Such effects might involve PPARγ receptors, although in silico and in vitro experiments strongly suggest that VCE-003.2 targets PPARγ by acting through two binding sites at the LBP, one that is sensitive to T0070907 (canonical binding site) and other that is not affected by this PPARγ antagonist (alternative binding site).
Additional file 1: Figure S1. Double immunofluorescence analysis of Cd68 (in green) and TH (in red) in the substantia nigra pars compacta of adult male mice at 3 weeks of being subjected to an intrastriatal injection of LPS. Top panels show both immunostainings in the contralateral (lesioned) and ipsilateral (non-lesioned) sides (scale bar = 50 μm), whereas bottom panels show the immunostaining for both markers and the merged image in the contralateral (lesioned) side (scale bar = 50 μm), proving the presence of Cd68 immunostaining associated with TH-positive cells, but a complete lack of overlapping, then demonstrating that they correspond to different cells (TH-positive neurons versus Cd68-positive microglial cells) (PDF 757 kb)12974_2018_1060_MOESM1_ESM.pdf
Additional file 2: Figure S2. BV2 cells were seeded at 1 × 105 in 60-mm dishes and 24 h later treated with RGZ or VCE-003.2 in the absence or the presence of LPS (50 ng/mL) for 6 h and the steady state levels of endogenous PPARγ and β-actin detected by western blot (PDF 105 kb)12974_2018_1060_MOESM2_ESM.pdf
Additional file 3: Supplementary information and Supplementary Figures S3–S5. Effects of VCE-003.2 in 6-hydroxydopamine-lesioned mice (PDF 564 kb)12974_2018_1060_MOESM3_ESM.pdf
Price DA, Martinez AA, Seillier A, Koek W, Acosta Y, Fernández E, et al. WIN55,212-2, a cannabinoid receptor agonist, protects against nigrostriatal cell loss in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson’s disease. Eur J Neurosci. 2009;29:2177–86. CrossRefPubMedPubMedCentral
Gómez-Gálvez Y, Palomo-Garo C, Fernández-Ruiz J, García C. Potential of the cannabinoid CB2 receptor as a pharmacological target against inflammation in Parkinson’s disease. Prog Neuro-Psychopharmacol Biol Psychiatry. 2016;64:200–8. CrossRef
Ternianov A, Pérez-Ortiz JM, Solesio ME, García-Gutiérrez MS, Ortega-Alvaro A, Navarrete F, et al. Overexpression of CB 2 cannabinoid receptors results in neuroprotection against behavioral and neurochemical alterations induced by intracaudate administration of 6-hydroxydopamine. Neurobiol Aging. 2012;33:421 e1–e16. CrossRef
Palkovits M, Brownstein J. Maps and guide to microdissection of the rat brain. Elsevier, 1988.
Wolf LK. New software and websites for the chemical enterprise. Chem Eng News. 2009;87:31.
Zhou M, Wu R, Dong W, Jacob A, Wang P. Endotoxin downregulates peroxisome proliferator-activated receptor-γ via the increase in TNF-α release. Am J Phys Regul Integr Comp Phys. 2008;294:R84–92.
Zizzo G, Cohen PL. The PPAR-γ antagonist GW9662 elicits differentiation of M2c-like cells and upregulation of the MerTK/Gas6 axis: a key role for PPAR-γ in human macrophage polarization. Inflamm (Lond). 2015;12:36. CrossRef
Oh YT, Lee JY, Lee J, Lee JH, Kim JE, Ha J et al. Oleamide suppresses lipopolysaccharide-induced expression of iNOS and COX-2 through inhibition of NFκB activation in BV2 murine microglial cells. Neurosci Lett 2010; 474: 148-153.
- Benefits of VCE-003.2, a cannabigerol quinone derivative, against inflammation-driven neuronal deterioration in experimental Parkinson’s disease: possible involvement of different binding sites at the PPARγ receptor
M. Luz Bellido
M. Ruth Pazos
- BioMed Central